Taken together, these data strongly support the notion that GNA13-induced TIC phenotype is mediated via activation of NFκB and JNK/MAPK-AP-1 signaling pathways, and that blocking these pathways can re-sensitize the HNSCC cells to cisplatin treatment. The gene discussed is GNA13; the disease is head and neck squamous cell carcinoma.